Novo Nordisk opens the first haemostasis research facility in the US
Danish company Novo Nordisk has set up Novo Nordisk Research US, the first haemostasis research facility in the US dedicated to life-threatening bleeding.
Danish company Novo Nordisk has set up Novo Nordisk Research US, the first haemostasis research facility in the US dedicated to life-threatening bleeding.
Researchers at the facility will investigate new therapies to prevent or stop critical bleeding, including exploration of treatments for intracerebral haemorrhage, trauma, stroke and other bleeding disorders.
Scientists at Novo Nordisk Research US will be collaborating with academic institutions and industries in the area to further advance medical innovation. The 30,000ft2 facility houses 21 full-time researchers, which Novo Nordisk intends to double by the end of the year.
'There are a number of research organisations in the US that are recognised for their excellence. They are an important reason for choosing to expand our presence here,' said Mads Krogsgaard Thomsen, chief science officer. He also noted the new centre, which represents a major expansion of Novo Nordisk's research in the area of haemostasis, is part of the ongoing internationalisation of the company's r&d.